Codexis Inc. (NASDAQ:CDXS)’s share price traded down 2.3% on Friday . The stock traded as low as $4.20 and last traded at $4.20, with a volume of 66,932 shares changing hands. The stock had previously closed at $4.30.

A number of research firms have recently commented on CDXS. Zacks Investment Research raised Codexis from a “sell” rating to a “hold” rating in a report on Wednesday, August 10th. HC Wainwright began coverage on Codexis in a report on Wednesday, June 1st. They set a “buy” rating and a $6.00 price target for the company.

The company has a 50-day moving average price of $4.21 and a 200-day moving average price of $3.83. The firm’s market capitalization is $172.96 million.

Codexis (NASDAQ:CDXS) last issued its quarterly earnings results on Tuesday, August 9th. The company reported $0.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.09. The business had revenue of $16 million for the quarter, compared to analysts’ expectations of $15.10 million. The business’s revenue was up 166.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.14) earnings per share. Equities analysts expect that Codexis Inc. will post ($0.20) earnings per share for the current fiscal year.

In other Codexis news, Director Bernard J. Kelley sold 12,643 shares of the stock in a transaction on Wednesday, August 24th. The stock was sold at an average price of $4.26, for a total transaction of $53,859.18. Following the completion of the transaction, the director now directly owns 234,906 shares of the company’s stock, valued at $1,000,699.56. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Vivo Ventures Vii, Llc sold 50,000 shares of the stock in a transaction on Monday, August 15th. The shares were sold at an average price of $4.27, for a total value of $213,500.00. The disclosure for this sale can be found here.

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.